UOC Microbiologia e Virologia, AO Ospedale San Carlo Borromeo, Milano, Italia.
Chemotherapy. 2011;57(5):426-33. doi: 10.1159/000330458. Epub 2011 Nov 26.
In 2004-2008, the epidemiological and clinical Infective Endocarditis Study Group (SEI) evaluated 852 cases of infective endocarditis. Staphylococcus aureus was the main involved pathogen (24.5%) and Enterococcus faecalis etiology was described in 11% of the cases. The aim of this study was to evaluate the in vitro activity of 12 antibiotics alone and in association against 27 strains of E. faecalis isolated from blood cultures of patients with infective endocarditis.
The results showed high in vitro activity of tigecycline, daptomycin and linezolid. A high synergistic effect was obtained with the association ceftriaxone-fosfomycin [fractional inhibitory concentration (FIC)(50) = 0.34, FIC(90) = 0.78]. Furthermore, ceftriaxone plus ampicillin presented additive results (FIC(50) = 0.66, FIC(90) = 1.00), and ceftriaxone plus fosfomycin and ceftriaxone plus ampicillin were significantly more active in vitro than each drug alone. The efficacy of ceftriaxone plus fosfomycin was confirmed by the association testing using the broth dilution technique.
Fosfomycin seems particularly significant and its association with ceftriaxone could be considered as a useful therapeutic option in medical treatment of E. faecalis infective endocarditis.
2004-2008 年,感染性心内膜炎研究组(SEI)评估了 852 例感染性心内膜炎患者。金黄色葡萄球菌是主要的病原体(24.5%),11%的病例由粪肠球菌引起。本研究的目的是评估 12 种抗生素单独和联合治疗 27 株粪肠球菌的体外活性,这些菌株均从感染性心内膜炎患者的血培养中分离得到。
研究结果表明,替加环素、达托霉素和利奈唑胺具有较高的体外活性。头孢曲松-磷霉素联合使用具有高度协同作用[半数抑制浓度(FIC)(50)=0.34,FIC(90)=0.78]。此外,头孢曲松联合氨苄西林具有相加作用(FIC(50)=0.66,FIC(90)=1.00),头孢曲松联合磷霉素和头孢曲松联合氨苄西林的体外活性均明显优于单独使用每种药物。联合肉汤稀释技术的药敏试验证实了头孢曲松联合磷霉素的疗效。
磷霉素具有显著的作用,其与头孢曲松的联合应用可能是治疗粪肠球菌感染性心内膜炎的一种有效治疗选择。